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Background
This study aims to detect Nevirapine (NVP) side effects
among patients started with lead in dose at initiation of
Anti Retroviral Therapy (ART) with CD4 count >250
cells/mm3 in female and CD4 count >400 cells/mm3 in
male.
Methods
Close monitoring was conducted for the detection of
NVP based side effects among ART - naïve patients
initiated on CD4 count >250 cells/mm3 among women
and CD4 count > 400 cells/mm3 are the study target at
Centre of Excellence (CoE), ART Centre, B. J. Medical
College, Civil Hospital, Ahmedabad, Gujarat, India.
Results
Total 5060 patients were initiated ART during the per-
iod of may 2005 to may 2009 at the institute. Among
this 3647 (72%) were initiated with NVP lead in dose as
per the Indian National ART Guidelines, Table 1.
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Table 1
Parameter Outcome
NVP lead in dose initiated patients 3647 (n)
Male 2408(66.02%)
Female 1239(33.97%)
Male with CD4 >400 cells/mm3 and initiated NVP lead in dose (n = 2408) 47(1.95%)
Female with CD4 >250 cells/mm3 and initiated NVP lead in dose (n = 1239) 112(9.03%)
NVP induced Rash Male (n = 47) 0
Female (n = 112) 5(4.46%)
NVP induced Hepatitis Male (n = 47) 1(2.12%)
Female (n = 112) 0
Male with CD4 <400 cells/mm3 and initiated NVP lead in dose (n = 2408) 1629(67.64%)
Female with CD4 <250 cells/mm3 and initiated NVP lead in dose (n = 1239) 838(67.63%)
NVP induced Rash Male (n = 1629) 19(1.16%)
Female (n = 838) 15(1.78%)
NVP induced Hepatitis Male (n = 1629) 5(0.30%)
Female (n = 838) 2(0.23%)
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Discussion
Skin Rash was recovered on substituting with another
NNRTI- Efavirenz (EFV) and the treatment was well tol-
erated. Hepatitis was managed with substitution to EFV
and close follow-up on ALT and AST. Though western
literature has a black box warning for use of NVP, this
data shows if closely monitored it could be given at
resources limited settings with CD4 counts >250 cells/
mm3 in females and >400 cells/mm3 males. Nevirapine
is cost effective molecule compared to Efavirenz and
when given in such conditions of higher CD4 need close
follow up.
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